

---

**HOUSE BILL 1062**

---

**State of Washington**

**69th Legislature**

**2025 Regular Session**

**By** Representatives Stonier, Corry, Parshley, Thai, and Macri

Prefiled 12/13/24.

1 AN ACT Relating to coverage for biomarker testing; adding a new  
2 section to chapter 48.43 RCW; adding a new section to chapter 41.05  
3 RCW; and adding a new section to chapter 74.09 RCW.

4 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF WASHINGTON:

5 NEW SECTION. **Sec. 1.** A new section is added to chapter 48.43  
6 RCW to read as follows:

7 (1) For health plans issued or renewed on or after January 1,  
8 2026, a health carrier shall include coverage for biomarker testing  
9 pursuant to the criteria established under subsection (2) of this  
10 section.

11 (2) Biomarker testing must be covered for the purposes of  
12 diagnosis, treatment, appropriate management, or ongoing monitoring  
13 of an enrollee's disease or condition when the test is supported by  
14 medical and scientific evidence including, but not limited to:

15 (a) Labeled indications for tests approved or cleared by the  
16 United States food and drug administration or indicated tests for a  
17 drug approved by the United States food and drug administration;

18 (b) Centers for medicare and medicaid services national coverage  
19 determinations or medicare administrative contractor local coverage  
20 determinations;

21 (c) Nationally recognized clinical practice guidelines; or

1 (d) Consensus statements.

2 (3) Health carriers shall ensure coverage as required in  
3 subsection (2) of this section is provided in a manner that limits  
4 disruptions in care including the need for multiple biopsies or  
5 biospecimen samples.

6 (4) For the purposes of this section:

7 (a) "Biomarker" means a characteristic that is objectively  
8 measured and evaluated as an indicator of normal biological  
9 processes, pathogenic processes, or pharmacologic responses to a  
10 specific therapeutic intervention. Biomarkers include but are not  
11 limited to gene mutations or protein expression.

12 (b) "Biomarker testing" means the analysis of a patient's tissue,  
13 blood, or other biospecimen for the presence of a biomarker.  
14 Biomarker testing includes but is not limited to single-analyte  
15 tests, multiplex panel tests, and whole genome sequencing.

16 (c) "Consensus statements" means statements that are:

17 (i) Developed by an independent, multidisciplinary panel of  
18 experts utilizing a transparent methodology and reporting structure  
19 and with a conflict of interest policy;

20 (ii) Aimed at specific clinical circumstances; and

21 (iii) Based on the best available evidence for the purpose of  
22 optimizing the outcomes of clinical care.

23 (d) "Nationally recognized clinical practice guidelines" means  
24 evidence-based clinical practice guidelines that:

25 (i) Are developed by independent organizations or medical  
26 professional societies utilizing a transparent methodology and  
27 reporting structure and with a conflict of interest policy;

28 (ii) Establish standards of care informed by a systematic review  
29 of evidence and an assessment of the benefits and costs of  
30 alternative care options; and

31 (iii) Include recommendations intended to optimize patient care.

32 NEW SECTION. **Sec. 2.** A new section is added to chapter 41.05  
33 RCW to read as follows:

34 (1) A health plan offered to public employees and their covered  
35 dependents under this chapter issued or renewed on or after January  
36 1, 2026, shall include coverage for biomarker testing pursuant to the  
37 criteria established under subsection (2) of this section.

38 (2) Biomarker testing must be covered for the purposes of  
39 diagnosis, treatment, appropriate management, or ongoing monitoring

1 of an enrollee's disease or condition when the test is supported by  
2 medical and scientific evidence including, but not limited to:

3 (a) Labeled indications for tests approved or cleared by the  
4 United States food and drug administration or indicated tests for a  
5 drug approved by the United States food and drug administration;

6 (b) Centers for medicare and medicaid services national coverage  
7 determinations or medicare administrative contractor local coverage  
8 determinations;

9 (c) Nationally recognized clinical practice guidelines; or

10 (d) Consensus statements.

11 (3) A health plan offered to public employees and their covered  
12 dependents shall ensure coverage as required in subsection (2) of  
13 this section is provided in a manner that limits disruptions in care  
14 including the need for multiple biopsies or biospecimen samples.

15 (4) For purposes of this section, "biomarker," "biomarker  
16 testing," "consensus statements," and "nationally recognized clinical  
17 practice guidelines" all have the same meaning as defined in section  
18 1 of this act.

19 NEW SECTION. **Sec. 3.** A new section is added to chapter 74.09  
20 RCW to read as follows:

21 (1) Beginning January 1, 2026, the authority shall provide  
22 coverage under this chapter for biomarker testing pursuant to the  
23 criteria established under subsection (2) of this section.

24 (2) Biomarker testing must be covered for the purposes of  
25 diagnosis, treatment, appropriate management, or ongoing monitoring  
26 of an enrollee's disease or condition when the test is supported by  
27 medical and scientific evidence including, but not limited to:

28 (a) Labeled indications for tests approved or cleared by the  
29 United States food and drug administration or indicated tests for a  
30 drug approved by the United States food and drug administration;

31 (b) Centers for medicare and medicaid services national coverage  
32 determinations or medicare administrative contractor local coverage  
33 determinations;

34 (c) Nationally recognized clinical practice guidelines; or

35 (d) Consensus statements.

36 (3) The authority shall ensure coverage as required in subsection  
37 (2) of this section is provided in a manner that limits disruptions  
38 in care including the need for multiple biopsies or biospecimen  
39 samples.

1           (4) In administering this program, the authority shall seek any  
2 available federal financial participation under the medical  
3 assistance program, as codified at Title XIX of the federal social  
4 security act, or any other federal funding sources that are now  
5 available or may become available.

6           (5) For purposes of this section, "biomarker," "biomarker  
7 testing," "consensus statements," and "nationally recognized clinical  
8 practice guidelines" all have the same meaning as defined in section  
9 1 of this act.

--- END ---